This table presents recent patent oppositions filed by Crispr Therapeutics Ag against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP3603679Rna-Guideded Transcriptional RegulationPRESIDENT AND FELLOWS OF HARVARD COLLEGEAug 11, 2022
EP3733847Composition For Cleaving A Target Dna Comprising A Guide Rna Specific For The Target Dna And Cas Protein-Encoding Nucleic Acid Or Cas Protein, And Use ThereofTOOLGEN INCORPORATEDJun 2, 2022
EP3327127Delivery, Engineering And Optimization Of Systems, Methods And Compositions For Sequence Manipulation And Therapeutic ApplicationsMASSACHUSETTS INSTITUTE OF TECHNOLOGYApr 7, 2021
EP3011031Delivery And Use Of The Crispr-Cas Systems, Vectors And Compositions For Hepatic Targeting And TherapyMASSACHUSETTS INSTITUTE OF TECHNOLOGYNov 13, 2020
EP3252160Crispr-Cas Component Systems, Methods And Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYOct 29, 2020
EP3144390Engineering Of Systems, Methods And Optimized Guide Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYMar 19, 2020
EP3064585Engineering And Optimization Of Improved Systems, Methods And Enzyme Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYFeb 10, 2020
EP3494997Inducible Dna Binding Proteins And Genome Perturbation Tools And Applications ThereofMASSACHUSETTS INSTITUTE OF TECHNOLOGYFeb 10, 2020
EP2940140Engineering Of Systems, Methods And Optimized Guide Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYNov 5, 2019
EP2931892Methods, Models, Systems, And Apparatus For Identifying Target Sequences For Cas Enzymes Or Crispr-Cas Systems For Target Sequences And Conveying Results ThereofMASSACHUSETTS INSTITUTE OF TECHNOLOGYFeb 28, 2019